<p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）预计将在 2025 年 3 月 30 日星期一市场开盘前发布其 2025 年第四季度财报。分析师预计该公司将在本季度宣布每股收益为（$0.41）。投资者可以在公司即将发布的 2025 年第四季度财报页面上找到电话会议的详细信息，最新的电话会议安排在 2026 年 3 月 25 日星期三东部时间下午 12:30。</p>
<p>获取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
<ul>
<li>按表现排名的最佳股票选择人工智能</li>
</ul>
<p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）最近于 3 月 19 日星期四发布了季度财报。该公司报告本季度每股收益为（$0.73），低于市场共识预期的（$0.43），差距为（$0.30）。分析师平均预计 Larimar Therapeutics 在当前财年将发布每股收益为$-1，下一财年为$-2。</p>
<h2>Larimar Therapeutics 股价上涨 0.4%</h2>
<p>Larimar Therapeutics 的股票在星期一以$4.49 开盘。该公司的市值为 4.6642 亿美元，市盈率为-2.03，贝塔值为 0.90。该公司的 50 日移动平均价格为$3.95，200 日移动平均价格为$3.92。Larimar Therapeutics 的 1 年最低价为$1.61，1 年最高价为$6.42。</p>
<h2>内部人士活动</h2>
<p>在其他新闻中，董事 James E. Flynn 于 2 月 27 日星期五购买了 5,000,000 股该股票，交易的平均价格为每股$5.00，总交易额为$25,000,000.00。完成收购后，该董事直接持有公司 10,622,957 股，估值约为$53,114,785。这笔交易代表其持股比例增加了 88.92%。该购买在向 SEC 的法律文件中披露，可以通过此超链接访问。目前，4.50% 的股票由内部人士持有。</p>
<h2>机构投资者对 Larimar Therapeutics 的看法</h2>
<p>一些机构投资者最近增加或减少了对该公司的持股。法国巴黎银行金融市场在第三季度将其在 Larimar Therapeutics 的持股增加了 75.8%。法国巴黎银行金融市场现在拥有 10,146 股该公司的股票，价值$33,000，在上个季度又购买了 4,376 股。美国世纪公司在第二季度将其在 Larimar Therapeutics 的持股增加了 7.8%。美国世纪公司现在拥有 69,285 股该公司的股票，价值$200,000，在上个季度又收购了 5,001 股。Price T Rowe Associates Inc. MD 在第四季度将其在 Larimar Therapeutics 的持股增加了 26.3%。Price T Rowe Associates Inc. MD 现在拥有 29,008 股该公司的股票，价值$111,000，在上个季度又收购了 6,038 股。巴克莱银行在第四季度将其在 Larimar Therapeutics 的持股增加了 10.7%。巴克莱银行现在拥有 78,470 股该公司的股票，价值$299,000，在上个季度又收购了 7,577 股。最后，Rhumbline Advisers 在第一季度将其在 Larimar Therapeutics 的持股增加了 15.7%。Rhumbline Advisers 现在拥有 65,018 股该公司的股票，价值$140,000，在上个季度又收购了 8,818 股。91.92% 的股票由机构投资者持有。</p>
<h2>分析师升级和降级</h2>
<p>LRMR 成为多份分析师报告的主题。Wedbush 在周五的报告中将 Larimar Therapeutics 的目标价格从$12.00 上调至$13.00，并给予该股票 “跑赢大盘” 的评级。花旗集团在 2 月 25 日星期三的研究报告中将 Larimar Therapeutics 的目标价格从$12.00 上调至$14.00，并给予该公司 “买入” 评级。Leerink Partners 在 1 月 5 日星期一的报告中将 Larimar Therapeutics 的评级提升至 “强烈买入”。Weiss Ratings 在 1 月 22 日星期四的研究报告中重新发布了对 Larimar Therapeutics 的 “卖出（d-）” 评级。最后，Lifesci Capital 在 2 月 24 日星期二的报告中将 Larimar Therapeutics 的评级提升至 “强烈买入”。两位股票研究分析师对该股票给予了 “强烈买入” 评级，七位给予了 “买入” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，共识目标价格为$16.43。</p>
<p><strong>阅读我们关于 LRMR 的最新股票报告</strong></p>
<h2>关于 Larimar Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Larimar Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于利用其新型细胞穿透肽技术平台开发罕见疾病的治疗方案。其主要产品候选药物 CTI-1601 目前正在进行针对弗里德里希共济失调的第二阶段 OLE 临床试验，这是一种罕见的、进行性且致命的遗传疾病。Larimar Therapeutics, Inc 总部位于宾夕法尼亚州巴拉金伍德。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票，胜过 Larimar Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxSTVI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxSTVI"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Larimar Therapeutics 吗？</h2>
<p>在你考虑 Larimar Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Larimar Therapeutics 并不在名单上。</p>
<p>虽然 Larimar Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看五只股票</p>

LRMR

<p>Larimar Therapeutics（纳斯达克代码：LRMR）将于 3 月 30 日公布 2025 年第四季度财报，分析师预测每股亏损 0.41 美元。该公司最近报告了上一季度每股亏损 0.73 美元，未能达到预期。当前股票交易价格为 4.49 美元，市值为 4.6642 亿美元。内部人士 James E. Flynn 购买了 500 万股，显著增加了他的持股比例。分析师的评级意见不一，普遍为 “买入”，目标价格为 16.43 美元</p>

<p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 12:30 PM ET.</p>
<div class="lb-trans"><p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）预计将在 2025 年 3 月 30 日星期一市场开盘前发布其 2025 年第四季度财报。分析师预计该公司将在本季度宣布每股收益为（$0.41）。投资者可以在公司即将发布的 2025 年第四季度财报页面上找到电话会议的详细信息，最新的电话会议安排在 2026 年 3 月 25 日星期三东部时间下午 12:30。</p>
</div><p>Get <strong>Larimar Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>按表现排名的最佳股票选择人工智能</li>
</ul>
</div><p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.30). On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Larimar Therapeutics（纳斯达克代码：LRMR - 获取免费报告）最近于 3 月 19 日星期四发布了季度财报。该公司报告本季度每股收益为（$0.73），低于市场共识预期的（$0.43），差距为（$0.30）。分析师平均预计 Larimar Therapeutics 在当前财年将发布每股收益为$-1，下一财年为$-2。</p>
</div><h2>Larimar Therapeutics Trading Up 0.4%</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 股价上涨 0.4%</h2>
</div><p>Larimar Therapeutics stock opened at $4.49 on Monday. The firm has a market capitalization of $466.42 million, a price-to-earnings ratio of -2.03 and a beta of 0.90. The firm's fifty day moving average price is $3.95 and its two-hundred day moving average price is $3.92. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.42.</p>
<div class="lb-trans"><p>Larimar Therapeutics 的股票在星期一以$4.49 开盘。该公司的市值为 4.6642 亿美元，市盈率为-2.03，贝塔值为 0.90。该公司的 50 日移动平均价格为$3.95，200 日移动平均价格为$3.92。Larimar Therapeutics 的 1 年最低价为$1.61，1 年最高价为$6.42。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部人士活动</h2>
</div><p>In other news, Director James E. Flynn bought 5,000,000 shares of the stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $5.00 per share, for a total transaction of $25,000,000.00. Following the completion of the acquisition, the director directly owned 10,622,957 shares in the company, valued at approximately $53,114,785. This trade represents a 88.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.50% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 James E. Flynn 于 2 月 27 日星期五购买了 5,000,000 股该股票，交易的平均价格为每股$5.00，总交易额为$25,000,000.00。完成收购后，该董事直接持有公司 10,622,957 股，估值约为$53,114,785。这笔交易代表其持股比例增加了 88.92%。该购买在向 SEC 的法律文件中披露，可以通过此超链接访问。目前，4.50% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Larimar Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Larimar Therapeutics 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in Larimar Therapeutics by 75.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company's stock valued at $33,000 after buying an additional 4,376 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Larimar Therapeutics by 7.8% in the second quarter. American Century Companies Inc. now owns 69,285 shares of the company's stock valued at $200,000 after acquiring an additional 5,001 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Larimar Therapeutics by 26.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,008 shares of the company's stock valued at $111,000 after acquiring an additional 6,038 shares in the last quarter. Barclays PLC increased its position in shares of Larimar Therapeutics by 10.7% during the fourth quarter. Barclays PLC now owns 78,470 shares of the company's stock valued at $299,000 after acquiring an additional 7,577 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Larimar Therapeutics by 15.7% during the first quarter. Rhumbline Advisers now owns 65,018 shares of the company's stock valued at $140,000 after acquiring an additional 8,818 shares during the last quarter. 91.92% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对该公司的持股。法国巴黎银行金融市场在第三季度将其在 Larimar Therapeutics 的持股增加了 75.8%。法国巴黎银行金融市场现在拥有 10,146 股该公司的股票，价值$33,000，在上个季度又购买了 4,376 股。美国世纪公司在第二季度将其在 Larimar Therapeutics 的持股增加了 7.8%。美国世纪公司现在拥有 69,285 股该公司的股票，价值$200,000，在上个季度又收购了 5,001 股。Price T Rowe Associates Inc. MD 在第四季度将其在 Larimar Therapeutics 的持股增加了 26.3%。Price T Rowe Associates Inc. MD 现在拥有 29,008 股该公司的股票，价值$111,000，在上个季度又收购了 6,038 股。巴克莱银行在第四季度将其在 Larimar Therapeutics 的持股增加了 10.7%。巴克莱银行现在拥有 78,470 股该公司的股票，价值$299,000，在上个季度又收购了 7,577 股。最后，Rhumbline Advisers 在第一季度将其在 Larimar Therapeutics 的持股增加了 15.7%。Rhumbline Advisers 现在拥有 65,018 股该公司的股票，价值$140,000，在上个季度又收购了 8,818 股。91.92% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>LRMR has been the topic of a number of analyst reports. Wedbush upped their target price on shares of Larimar Therapeutics from $12.00 to $13.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday. Citigroup lifted their price target on Larimar Therapeutics from $12.00 to $14.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, February 25th. Leerink Partners raised Larimar Therapeutics to a &#34;strong-buy&#34; rating in a report on Monday, January 5th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Finally, Lifesci Capital upgraded Larimar Therapeutics to a &#34;strong-buy&#34; rating in a report on Tuesday, February 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $16.43.</p>
<div class="lb-trans"><p>LRMR 成为多份分析师报告的主题。Wedbush 在周五的报告中将 Larimar Therapeutics 的目标价格从$12.00 上调至$13.00，并给予该股票 “跑赢大盘” 的评级。花旗集团在 2 月 25 日星期三的研究报告中将 Larimar Therapeutics 的目标价格从$12.00 上调至$14.00，并给予该公司 “买入” 评级。Leerink Partners 在 1 月 5 日星期一的报告中将 Larimar Therapeutics 的评级提升至 “强烈买入”。Weiss Ratings 在 1 月 22 日星期四的研究报告中重新发布了对 Larimar Therapeutics 的 “卖出（d-）” 评级。最后，Lifesci Capital 在 2 月 24 日星期二的报告中将 Larimar Therapeutics 的评级提升至 “强烈买入”。两位股票研究分析师对该股票给予了 “强烈买入” 评级，七位给予了 “买入” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，共识目标价格为$16.43。</p>
</div><p><strong>Read Our Latest Stock Report on LRMR</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 LRMR 的最新股票报告</strong></p>
</div><h2>About Larimar Therapeutics</h2>
<div class="lb-trans"><h2>关于 Larimar Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.</p>
<div class="lb-trans"><p>Larimar Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于利用其新型细胞穿透肽技术平台开发罕见疾病的治疗方案。其主要产品候选药物 CTI-1601 目前正在进行针对弗里德里希共济失调的第二阶段 OLE 临床试验，这是一种罕见的、进行性且致命的遗传疾病。Larimar Therapeutics, Inc 总部位于宾夕法尼亚州巴拉金伍德。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Larimar Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票，胜过 Larimar Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFJNUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LRMR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Larimar Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Larimar Therapeutics 吗？</h2>
</div><p>Before you consider Larimar Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Larimar Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Larimar Therapeutics 并不在名单上。</p>
</div><p>While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Larimar Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看五只股票</p>
</div>

Larimar Therapeutics (LRMR) 预计将在周一公布财报